154 related articles for article (PubMed ID: 15599999)
1. New progress in treatment of hormone-refractory prostate cancer.
Ahmad K
Lancet Oncol; 2004 Dec; 5(12):706. PubMed ID: 15599999
[No Abstract] [Full Text] [Related]
2. [Effective chemotherapy for hormone-refractory prostate cancer: docetaxel-prednisone].
Batman E; de Wit R
Ned Tijdschr Geneeskd; 2005 Oct; 149(44):2442-5. PubMed ID: 16285357
[TBL] [Abstract][Full Text] [Related]
3. [Significance of docetaxel in the chemotherapy of hormone-refractory prostate cancer].
Wolff JM
Onkologie; 2003 Dec; 26 Suppl 7():37-40. PubMed ID: 14716141
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for prostate cancer: finally an advance!
Gulley J; Dahut WL
Am J Ther; 2004; 11(4):288-94. PubMed ID: 15266221
[TBL] [Abstract][Full Text] [Related]
5. [Docetaxel and prostate cancer].
Ferrero JM
Bull Cancer; 2004 Feb; 91(2):172-7. PubMed ID: 15047457
[TBL] [Abstract][Full Text] [Related]
6. Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?
Protheroe A
Nat Clin Pract Oncol; 2005 Feb; 2(2):68-9. PubMed ID: 16264873
[No Abstract] [Full Text] [Related]
7. NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
Jilani A; George E; Adler AI
Lancet Oncol; 2012 Jun; 13(6):573-4. PubMed ID: 22833888
[No Abstract] [Full Text] [Related]
8. Cabazitaxel, a taxane for men with hormone-refractory metastatic prostate cancer.
Wilkes GM
Oncology (Williston Park); 2010 Oct; 24(10 Suppl):46-8. PubMed ID: 21275327
[No Abstract] [Full Text] [Related]
9. [Therapy of hormone refractory prostate cancer: new standards, new trends].
Wülfing C; Bierer S; Bögemann M; Piechota H; Hertle L
Aktuelle Urol; 2005 Aug; 36(4):342-8. PubMed ID: 16110408
[TBL] [Abstract][Full Text] [Related]
10. Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients.
Miyoshi Y; Uemura H; Nakamura M; Hasumi H; Sugiura S; Makiyama K; Nakaigawa N; Kishida T; Ogawa T; Yao M; Kubota Y
Int J Clin Oncol; 2005 Jun; 10(3):182-6. PubMed ID: 15990966
[TBL] [Abstract][Full Text] [Related]
11. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
Mathew P; Thall PF; Jones D; Perez C; Bucana C; Troncoso P; Kim SJ; Fidler IJ; Logothetis C
J Clin Oncol; 2004 Aug; 22(16):3323-9. PubMed ID: 15310776
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel for the treatment of prostate cancer.
Gilbert DC; Parker C
Future Oncol; 2005 Jun; 1(3):307-14. PubMed ID: 16556003
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel improves survival in metastatic androgen-independent prostate cancer.
Price N
Clin Prostate Cancer; 2004 Jun; 3(1):18-20. PubMed ID: 15279685
[No Abstract] [Full Text] [Related]
14. Chemotherapy combination shows efficacy in hormone-refractory prostate cancer.
Oncology (Williston Park); 1999 Jul; 13(7):1014. PubMed ID: 10442347
[No Abstract] [Full Text] [Related]
15. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
Van Poppel H
Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173
[TBL] [Abstract][Full Text] [Related]
16. Taxanes in hormone-refractory prostate cancer.
Kang MH; Figg WD; Dahut W
Cancer Pract; 1999; 7(5):270-2. PubMed ID: 10687598
[No Abstract] [Full Text] [Related]
17. Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles.
Kramer G; Schwarz S; Hägg M; Havelka AM; Linder S
Br J Cancer; 2006 Jun; 94(11):1592-8. PubMed ID: 16685278
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel for hormone-refractory prostate cancer.
Haines I
Lancet; 2008 Oct; 372(9648):1461; author reply 1461-2. PubMed ID: 18970973
[No Abstract] [Full Text] [Related]
19. Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy.
Oh WK; George DJ; Tay MH
Clin Prostate Cancer; 2005 Jun; 4(1):61-4. PubMed ID: 15992464
[TBL] [Abstract][Full Text] [Related]
20. Advances in prostate cancer chemotherapy: a new era begins.
Pienta KJ; Smith DC
CA Cancer J Clin; 2005; 55(5):300-18; quiz 323-5. PubMed ID: 16166075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
